The pathologic outcomes and efficacy of epothilone treatment following traumatic brain injury is determined by age.
Age Factors
Aging
/ pathology
Animals
Astrocytes
/ pathology
Axons
/ pathology
Brain Injuries, Traumatic
/ drug therapy
Disease Models, Animal
Epothilones
/ pharmacology
Longevity
Male
Mice, Inbred C57BL
Microglia
/ pathology
Neocortex
/ pathology
Nerve Degeneration
/ pathology
Neuroglia
/ pathology
Neurons
/ pathology
Treatment Outcome
Age at injury
Axonal degeneration
Cytoskeleton
Epothilones
Glia
Traumatic brain injury
Journal
Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
17
01
2020
revised:
27
03
2020
accepted:
28
03
2020
pubmed:
2
6
2020
medline:
16
1
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
Traumatic brain injury (TBI) can affect individuals at any age, with the potential of causing lasting neurologic consequences. The lack of effective therapeutic solutions and recommendations for patients that acquire a TBI can be attributed, at least in part, to an inability to confidently predict long-term outcomes following TBI, and how the response of the brain differs across the life span. The purpose of this study was to determine how age specifically affects TBI outcomes in a preclinical model. Male Thy1-YFPH mice, that express yellow fluorescent protein in the cytosol of a subset of Layer V pyramidal neurons in the neocortex, were subjected to a lateral fluid percussion injury over the right parietal cortex at distinct time points throughout the life span (1.5, 3, and 12 months of age). We found that the degree of neuronal injury, astrogliosis, and microglial activation differed depending on the age of the animal when the injury occurred. Furthermore, age affected the initial injury response and how it resolved over time. Using the microtubule stabilizing agent Epothilone D, to potentially protect against these pathologic outcomes, we found that the neuronal response was different depending on age. This study clearly shows that age must be taken into account in neurologic studies and preclinical trials involving TBI, and that future therapeutic interventions must be tailored to age.
Identifiants
pubmed: 32480164
pii: S0197-4580(20)30114-7
doi: 10.1016/j.neurobiolaging.2020.03.023
pii:
doi:
Substances chimiques
Epothilones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-96Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.